Elizabeth R. Volkmann

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

Donald P. Tashkin, Michael D. Roth, Philip J. Clements et al. · The Lancet Respiratory Medicine · 2016 · 1.1K citations

Medicine, Pharmacology, Pharmacotherapy +11

Dysfunctional proinflammatory high‐density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus

Maureen McMahon, Jennifer Grossman, Brian J. Skaggs et al. · Arthritis & Rheumatism · 2009 · 216 citations · Full text

Veterinary Medicine, Pathobiology, Inflammation +11

Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts

Elizabeth R. Volkmann, Donald P. Tashkin, Myung‐Shin Sim et al. · Annals of the Rheumatic Diseases · 2018 · 198 citations

Public Health, Biostatistics, Pharmacotherapy +13

Treatment of Systemic Sclerosis–associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline

Ganesh Raghu, Sydney B. Montesi, Richard M. Silver et al. · American Journal of Respiratory and Critical Care Medicine · 2023 · 160 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +16

Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis–Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II

Elizabeth R. Volkmann, Donald P. Tashkin, Ning Li et al. · Arthritis & Rheumatology · 2017 · 159 citations

Medicine, Pharmacology, Pharmacotherapy +14